AI assistant
Pharnext Environmental & Social Information 2017
1594_rns_2017-07-10_d5816c69-29c3-4df8-8db8-9d3bc34380a2.html
Environmental & Social Information
Open in viewerOpens in your device viewer
News Details
Corporate | 10 July 2017 17:46
Pharnext to Present PXT864 Data at the Alzheimer’s Association International Conference 2017
DGAP-News: Pharnext S.A. / Key word(s): Conference
10.07.2017 / 17:46
The issuer is solely responsible for the content of this announcement.
Pharnext to Present PXT864 Data at the Alzheimer’s Association International Conference 2017
Paris, France, 5:45pm, July 10, 2017 (CEST) – Pharnext SA (FR00111911287 – ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that data related to PXT864, the Company’s lead PLEODRUG(TM), in development for the treatment of Alzheimer’s disease (AD), will be presented in two posters at the Alzheimer’s Association International Conference 2017 (AAIC), July 16-20, in London, England.
Details are as follow:
| Date | Time | Title |
| Monday July 17, 2017 |
9:30am to 4:15pm BST | Poster #P2-005 “Treatment with PXT864 Showed Stabilisation of Cognitive Disability in Mild Alzheimer’s Disease after 36 Weeks.” J. Touchon et al. |
| Tuesday July 18, 2017 |
9:30am to 4:15pm BST | Poster #P3-047 “A Combination of Acamprosate and Baclofen (PXT864) Synergizes with Standards of Care for the Treatment of Alzheimer’s Disease.” N. Cholet et al. |
PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice-daily. PXT864 acts through a new mechanism of action that targets metabolic imbalance in the brain of patients suffering from neurodegenerative diseases. PXT864’s most advanced indication is Alzheimer’s disease. Development in other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is also planned.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY(TM). The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG(TM) offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
CONTACTS
| Pharnext Pierre Schwich Chief Financial Officer [email protected] +33 (0)1 41 09 22 30 |
Pharnext René Goedkoop Chief Medical Officer [email protected] +33 (0)1 41 09 22 30 |
|
| Investor Relations (Europe) MC Services AG Anne Hennecke [email protected] +49 211 529252 22 |
Investor Relations (U.S.) Stern Investor Relations, Inc. Sarah McCabe [email protected] +1 212-362-1200 |
Financial Communication (France) NewCap Emmanuel Huyn [email protected] +33 (0)1 44 71 20 40 |
| Media Relations (Europe) ALIZE RP Caroline Carmagnol Margaux Pronost [email protected] +33 (0)1 44 54 36 64 |
Media Relations (U.S.) Russo Partners Tony Russo Scott Santiamo [email protected] [email protected] +1 212-845-4251 +1 718-344-5843 |
10.07.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de